Metagen Therapeutics, which develops therapies and drugs using gut microbiota, raises ¥190 million in the first close of its Series B extension round. The financing is conducted through a third-party allotment, and the company announces the total on the 4th.
Metagen Therapeutics completes a Series B financing, raising ¥3.52 billion for its work in fecal microbiota transplantation. The company promotes medical and drug discovery based on gut microbiota research, and the round brings its total funding to ¥5.46 billion, according to the announcement.
Metagen Therapeutics, a company engaged in microbiome drug discovery, raises approximately ¥2.32 billion in the first and second closings of its Series B round. The company announces the combined financing on the 8th, identifying the amount as the total raised across both closings.
Metagen Therapeutics, Inc. and FRONTEO, Inc. launch a joint research collaboration applying microbiome research to drug discovery. The companies announce the collaboration in Tokyo on June 30, 2025, using FRONTEO’s AI drug discovery support service to address an area of growing global attention.
